eful for patients with Lou Gehrig's Disease and bed rest patients, as it would help arrest the loss of bone and muscle mass. Wrubel hopes to bring Cydan Develop- ment, a venture-capital backed orphan drug developer, to their upcoming fall conference in the Netherlands. As for the Topics, they were e